Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, et al. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024;14:87.

Article  PubMed  PubMed Central  Google Scholar 

Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.

Article  PubMed  PubMed Central  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. New England J Med. 2023;390:301–13.

Mateos M-V, Paiva B, Cedena Romero MT, Puig N, Sureda Balari AM, Oriol A, et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and Prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 Years. Blood. 2023;142:209.

Article  Google Scholar 

Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36:1066–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien M-L, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04. Blood. 2023;142:207.

Article  Google Scholar 

Callander N, Silbermann R, Kaufman JL, Godby KN, Laubach JP, Schmidt TM, et al. Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the griffin and master studies. Blood. 2022;140:10144–7.

Article  Google Scholar 

Bal S, Schmidt TM, Costa LJ, Callander NS. Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy. Leuk Lymphoma. 2022;63:1–11.

Article  Google Scholar 

Mohty M, Avet-Loiseau H, Malard F, Harousseau J-L. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood. 2023;142:1509–17.

Article  CAS  PubMed  Google Scholar 

Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. JAMA Oncol. 2021;7:862–8.

Article  PubMed  PubMed Central  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890–901.

Article  CAS  PubMed  Google Scholar 

Leypoldt LB, Tichy D, Besemer B, H„nel M, Raab MS, Mann C, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clinic Oncol. 2023;42:26–37.

Article  Google Scholar 

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, et al. Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142:4.

Article  Google Scholar 

O’Donnell E, Mo C, Yee AJ, Nadeem O, Laubach J, Rosenblatt J, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial. The Lancet Haematology. 2024. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00070-X/abstract?showall=true%3D.